Trial Profile
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs NZV 930 (Primary) ; Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 02 Nov 2022 Status changed from active, no longer recruiting to suspended.
- 29 Sep 2022 Planned End Date changed from 15 Sep 2022 to 13 Oct 2022.
- 29 Sep 2022 Planned primary completion date changed from 15 Sep 2022 to 13 Oct 2022.